Differentiated thyroid carcinoma

Related records

Broader conditions (17)

• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine gland neoplasm
• Endocrine system disorder
• Epithelial neoplasm
• Human disease
• Malignant endocrine neoplasm
• Neoplasm
• Neoplastic disease or syndrome
• Thyroid cancer
• Thyroid gland carcinoma
• Thyroid gland disorder
• Thyroid tumor

Narrower conditions (19)

• Columnar cell variant thyroid gland papillary carcinoma
• Familial medullary thyroid carcinoma
• Familial papillary or follicular thyroid carcinoma
• Medullary thyroid gland carcinoma
• Multicentric papillary thyroid carcinoma
• Papillary thyroid Microcarcinoma
• Tall cell variant thyroid gland papillary carcinoma
• Thyroid cancer, nonmedullary, 1
• Thyroid cancer, nonmedullary, 2
• Thyroid cancer, nonmedullary, 3
• Thyroid cancer, nonmedullary, 4
• Thyroid cancer, nonmedullary, 5
• Thyroid carcinoma, nonmedullary, with or without cell oxyphilia
• Thyroid gland diffuse sclerosing papillary carcinoma
• Thyroid gland follicular carcinoma
• Thyroid gland papillary and follicular carcinoma
• Thyroid gland papillary carcinoma
• Thyroid Hurthle cell carcinoma
• Trabecular follicular adenocarcinoma

Trials (21)

• A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
• A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
• Bethesda Classification and Risk Stratification in Differentiated Thyroid Carcinoma
• Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer
• Decision Aid Efficacy in Low Risk Thyroid Cancer
• Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
• I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
• Nintedanib(BIBF1120) in Thyroid Cancer
• OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation
• Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
• Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
• Robotic Surgery Via Bilateral Axillo-breast Approach for Relatively Low-risk Papillary Thyroid Carcinoma With Lateral Cervical Lymph Node Metastasis: a Safe and Effective Cosmetic Procedure in the Context of Prevalent Thyroid Ultrasound Screening
• Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
• Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.
• Spanish Study for Molecular Characterization of Thyroid Carcinoma
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
• Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
• The EMIRATES Study

Approved drugs (3)

• Lenvatinib
• Levothyroxine sodium
• Liothyronine sodium

Drugs in development (69)

• Adebrelimab Phase 2
• Avelumab Phase 1
• Avutometinib Phase 2
• Benmelstobart Phase 2
• Cabozantinib Phase 3
• Cabozantinib S-malate Phase 2
• Camrelizumab Phase 2
• Capecitabine Phase 2
• Catequentinib Phase 2
• Catequentinib hydrochloride Phase 2
• Cediranib maleate Phase 1
• Celecoxib Phase 2
• Cisplatin Phase 2
• CM-4307 Phase 2
• Cobimetinib Phase 2
• Cyclophosphamide Phase 2
• Dabrafenib Phase 3
• Defactinib Phase 2
• Denosumab Phase 2
• Doxorubicin hydrochloride Phase 2

Other linked drugs (6)

• Alendronate sodium
• Liothyronine
• Liothyronine I 131
• Metformin
• Sacituzumab tirumotecan
• Tislelizumab